Seroreactivity against PTEN-induced putative kinase 1 (PINK1) in Turkish patients with Behçet's disease

Clinical and Experimental Rheumatology

Volumn 27, Issue 2 SUPPL.53, 2009, Pages

  Vural, Burcak ^a   Demirkan, Ayse ^b   Ugurel, Elif ^b   Kalaylioglu Wheeler, Zeynep ^b   Esen, Bahar Artim ^b   Gure, Ali O ^b   Gül, Ahmet ^b   Ozbek, Ugur ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b NONE

Author keywords

ANKRDA1; Autoantigen; Beh et's disease; PINK1; SWAP70

Indexed keywords

ANKYRIN; ANKYRIN REPEAT DOMAIN 20 FAMILY MEMBER A1; AUTOANTIGEN; HLA B ANTIGEN; IMMUNOGLOBULIN G; PROTEIN IFIT2; PROTEIN SERINE THREONINE KINASE; PTEN INDUCED PUTATIVE KINASE 1; RABAPTIN 5; SWITCH ASSOCIATED PROTEIN 70; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ANTIGEN PURIFICATION; ARTICLE; BEHCET DISEASE; CONTROLLED STUDY; DNA LIBRARY; FEMALE; GENE FREQUENCY; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEROLOGY; SEROPREVALENCE; TURKEY (REPUBLIC);

ADULT; AUTOANTIBODIES; BEHCET SYNDROME; DNA-BINDING PROTEINS; FEMALE; GENE LIBRARY; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; MALE; NUCLEAR PROTEINS; PROTEIN KINASES; PROTEINS; TURKEY; VESICULAR TRANSPORT PROTEINS;

EID: 70350141941     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. SAKANE T, TAKENO M, SUZUKI N et al.: Behçet's disease. N Engl J Med 1999; 341: 1284-1291
2. VERITY DH, MARR JE, OHNO S, WALLACE GR, STANFORD MR: Behçet's disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens 1999; 54: 213-220
3. GÜL A, INANC, M, OCAL L et al.: Familial aggregation of Behçet's disease in Turkey. Ann Rheum Dis 2000; 59: 622-625
4. ZIERHUT M, MIZUKI N, OHNO S et al.: Cell Mol Life Sci 2003; 60: 1903-1922
5. STOJANOV S, KASTNER DL: Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 2005; 17: 586-599
6. OHNO S, OHGUCHI M, HIROSE S, MATSUDA H, WAKISAKA A, AIZAWA M: Close association of HLA-Bw51 with Behçet's disease. Arch Ophthalmol 1982; 100: 1445-1458
7. TAKEMOTO Y, NARUSE T, NAMBA K et al.: Re-evaluation of heterogeneity in HLA-B*510101 associated with Behçet's disease. Tissue Antigens 2008 Aug 12.
8. MIZUKI N, MEGURO A, TOHNAI I, GÜL A, OHNO S, MIZUKI N: Association of Major Histocompatibility Complex Class I Chain-Related Gene A and HLA-B Alleles with Behçet's Disease in Turkey. Jpn J Ophthalmol 2007; 51: 431-436
9. PARK K, KIM N, NAM J, BANG D, LEE ES: Association of TNFA promoter region haplotype in Behçet's Disease. J Korean Med Sci 2006; 21: 596-601.
10. AHMAD T, WALLACE GR, JAMES T et al.: Mapping the HLA association in Behçet's disease: a role for tumor necrosis factor polymorphisms? Arthritis Rheum 2003; 48: 807-13.
11. HIROHATA S, OKA H, MIZUSHIMA Y et al.: Streptococcal-related antigens stimulate production of IL-6 and interferon-gamma by T cells from patients with Behçet's Disease. Cell Immunol 1992; 140: 410-419
12. LEE KH, CHUNG HS, KIM HS: Human alpha-enolase from endothelial cells as a target antigen of anti-endothelial cell antibody in Behçet's disease. Arthritis Rheum 2003; 48: 2025-2035
13. MAHESH SP, LI Z, BUGGAGE R et al.: Alpha tropomyosin as a self-antigen in patients with Behçet's disease. Clin Exp Immunol 2005; 140: 368-375 (Pubitemid 40559166)
14. MOR F, WEINBERGER A, COHEN IR: Identification of alpha-tropomyosin as a target self-antigen in Behçet's syndrome. Eur J Immunol 2002; 32: 356-365
15. JOBIN D, THILLAYE B; DE KOZAK Y, SAINTELAUDY J, FAURE JP, LE HOANG P: Severe retinochoroidopathy: variations of humoral and cellular immunity to S-antigen in a longitudinal study. Curr Eye Res 1990; 9 (Suppl.): 91-96
16. YAMAMOTO JH, FUJINO Y, LIN C, NIEDA M, JUJI T, MASUDA K: S-antigen specific T cell clones from a patient with Behçet's disease. Br J Ophthalmol 1994; 78: 927-932
17. TANAKA T, YAMAKAWA N, KOIKE N, SUZUKI J, MIZUNO F, USUI M: Behçet's disease and antibody titers to various heat-shock protein 60s. Ocul Immunol Inflamm 1999; 7: 69-74.
18. SAHIN U, TÜRECI O, PFREUNDSCHUH M: Serological identification of human tumor antigens. Curr Opin Immunol 1997; 9: 709-16.
19. CHEN Y-T: Serological expression cloning (SEREX) approach to defining human tumor antigens. Cancer Immunity: March, 2004 (www.cancerimmunity.org)
20. JAGER D: Potential target antigens for immunotherapy identified by serological expression cloning (SEREX). Methods Mol Biol 2007; 360: 319-326
21. UCHIDA K, AKITA Y, MATSUO K et al.: Identification of specific autoantigens in Sjögren's syndrome by SEREX, Immunology 2005; 116: 53-63.
22. JEOUNG D, LIM Y, LEE EB et al.: Identification of autoantibody against poly (ADP-ribose) polymerase (PARP) fragment as a serological marker in systemic lupus erythematosus. J Autoimmun 2004; 22: 87-94.
23. SCHMITS R, KUBUSCHOK B, SCHUSTER S, PREUSS K-D, PFREUNDSCHUH M: Analysis of the B cell repertoire against autoantigens in patients with giant cell arteritis and polymyalgia rheumatica. Clin Exp Immunol 2002; 127: 370-385
24. JEOUNG DI, BONG LEE E et al.: Autoantibody to DNA binding protein B as a novel serologic marker in systemic sclerosis. Biochem Biophys Res Commun 2002; 299: 549-554
25. LU Y, YE P, CHEN S, TAN EM, CHAN EKL: Identification of kinectin as a novel Behçet's disease autoantigen. Arthritis Res Ther 2005; 7: R1133-R1139.
26. DELUNARDO F, CONTI F, MARGUTTI P: Identification and characterization of the carboxy-terminal region of Sip-1, a novel autoantigen in Behçet's disease. Arthritis Res Ther 2006; 8: R71-R79.
27. OKUNUKI Y, USUI Y, TAKEUCHI M et al.: Proteomic surveillance of autoimmunity in Behçet's disease with uveitis: Selenium binding protein is a novel autoantigen in Behçet's disease. Exp Eye Res 2007; 84: 823-831
28. INTERNATIONAL STUDY GROUP FOR BEHCET'S DISEASE (ISGBD): Criteria for diagnosis of Behçet's disease. Lancet 1990; 335: 1078-80.
29. BUNCE M, FANNING GC, WELSH KI: Comprehensive, serologically equivalent DNA typing for HLA-B by PCR using sequence-specific primers (PCR-SSP). Tissue Antigens 1995; 45:81-90.
30. BEILINA A, VAN DER BRUG M, AHMAD R et al: Mutations in PTENinduced putative kinase 1 associated with recessive Parkinsonism have differential effects on protein stability. Proc Natl Acad Sci U S A 2005; 102: 5703-5708
31. PRIDGEON JW, OLZMANN JA, CHIN L-S, LI L: PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol 2007; 5: 1494-1503
32. SILVESTRI L, CAPUTO V, BELLACCHIO E: Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive Parkinsonism. Hum Mol Genet 2005; 14: 3477-3492
33. WEIHOFEN A, OSTASZEWSKI B, MINAMI Y, SELKOE DJ: Pink1 Parkinson mutations, the Cdc37/Hsp90 chaperones and Parkin all influence the maturation or subcellular distribution of Pinkl. Hum Mol Genet 2005; 17: 602-616
34. LIN W, KANG UJ: Characterization of PINK1 processing, stability, and subcellular localization. J Neurochem 2008; 106: 464-474
35. MORIWAKI Y, KIM YJ, IDO Y et al.: L347P PINKI mutant that fails to bind to Hsp90/Cdc37 chaperones is rapidly degraded in a proteasome-dependent manner. Neurosci Res 2008; 61: 43-48
36. HUA G, ZHANG Q, FAN Z: Heat shock protein 75 (TRAP1) antagonizes reactive oxygen species generation and protects cells from granzyme M-mediated apoptosis. J Biol Chem 2007; 282: 20553-20560
37. PLUN-FAVREAU H, KLUPSCH K, MOISOI N: The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nat Cell Biol 2007; 9: 1243-1252
38. HENN IH, BOUMAN L, SCHLEHE JS et al.: Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling. J Neurosci 2007; 27: 1868-1878
39. PARK J, LEE SB, LEE S et al.: Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by Parkin. Nature 2006; 441: 1157-1161 (Pubitemid 43990737)
40. SEGLEN PO, GORDON PB: 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. Proc Natl Acad Sci U S A 1982; 79: 1889-1892
41. FENG XG, YE S, LU Y et al.: Antikinectin autoantibody in Behçet's disease and several other autoimmune connective tissue diseases. Clin Exp Rheumatol 2007; 25: S80-5.